Sorafenib and Temsirolimus in Treating Patients With Metastatic, Recurrent, or Unresectable Melanoma
Status:
Withdrawn
Trial end date:
2012-02-01
Target enrollment:
Participant gender:
Summary
This phase II portion of the trial is studying the side effects and best dose of temsirolimus
when given together with sorafenib and to see how well they work in treating patients with
metastatic, recurrent, or unresectable melanoma. Sorafenib and temsirolimus may stop the
growth of tumor cells by blocking some of the enzymes needed for cell growth. Sorafenib may
also stop the growth of tumor cells by blocking blood flow to the tumor. Giving sorafenib
together with temsirolimus may kill more tumor cells.